← back to search

Scott F. Huntington

Yale Cancer Center · US
Area of research
Pathology and Forensic Medicine · Genetics
Research interest
Research interests include Lymphoma Diagnosis and Treatment, Chronic Lymphocytic Leukemia Research, Acute Myeloid Leukemia Research, and CAR-T cell therapy research.
h-index
28
citations
2,950
works
270
NIH funding
primary concept
Medicine
email

Recent publications

Real-world patterns and sequences of targeted therapy use in chronic lymphocytic leukemia and small lymphocytic lymphoma in the United States: a longitudinal study
Leukemia & lymphoma/Leukemia and lymphoma 2024cited by 7position: firstdoi
Loncastuximab in high-risk and heavily pretreated relapsed / refractory diffuse large B-cell lymphoma: a real-world analysis from 21 US centers
Haematologica 2024cited by 6position: middledoi
Brentuximab vedotin plus AVD for Hodgkin lymphoma: incidence and management of peripheral neuropathy in a multisite cohort
Blood Advances 2023cited by 15position: middledoi
ABCL-455 Multicenter Retrospective Analysis of Single-Route Prophylaxis in Aggressive B-Cell Lymphomas
Clinical Lymphoma Myeloma & Leukemia 2022cited by 0position: middledoi
Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions
Blood 2021cited by 94position: middledoi
COVID-19 in patients with CLL: improved survival outcomes and update on management strategies
Blood 2021cited by 70position: middledoi
Cost-Effectiveness of First-Line Versus Second-Line Use of Daratumumab in Older, Transplant-Ineligible Patients With Multiple Myeloma
Journal of Clinical Oncology 2021cited by 39position: lastdoi
Outcomes of COVID-19 in patients with CLL: a multicenter international experience
Blood 2020cited by 318position: middledoi
Chromosome 1 abnormalities and survival of patients with multiple myeloma in the era of novel agents
Blood Advances 2020cited by 52position: middledoi
Anti-CD47 Antibody, CC-90002, in Combination with Rituximab in Subjects with Relapsed and/or Refractory Non-Hodgkin Lymphoma (R/R NHL)
Blood 2019cited by 35position: middledoi
R‐<scp>CHOP </scp><i>versus</i> dose‐adjusted R‐<scp>EPOCH</scp> in frontline management of primary mediastinal B‐cell lymphoma: a multi‐centre analysis
British Journal of Haematology 2017cited by 99position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Smith Giri · O'Neal Comprehensive Cancer Center2 papers (2020–2021)Natalia Neparidze · Yale Cancer Center2 papers (2020–2021)Alejandro Martı́n · Centro de Investigación Biomédica en Red de Cáncer1 papers (2019–2019) · 1 papers (2019–2019)Kishan Patel · Yale Cancer Center1 papers (2021–2021)Kristen Hege · Independent Sector1 papers (2019–2019)Wendy Y. Cheng · Columbia University1 papers (2024–2024)Xin Wei · Dalian Medical University1 papers (2019–2019)Mei Sheng Duh · Amgen (United States)1 papers (2024–2024) · 1 papers (2017–2017)Michael R. Burgess · Bristol-Myers Squibb (United States)1 papers (2019–2019) · 1 papers (2017–2017)Amer M. Zeidan · Yale Cancer Center1 papers (2020–2020)Charalambos Andreadis · UCSF Helen Diller Family Comprehensive Cancer Center1 papers (2019–2019)Timothy S. Fenske · Medical College of Wisconsin1 papers (2017–2017)Daniel O. Persky · Universidad San Carlos1 papers (2019–2019)Nilanjan Ghosh · Wake Forest Baptist Comprehensive Cancer Center1 papers (2017–2017)Ying Fei Li · Novartis (Switzerland)1 papers (2019–2019)Raúl Córdoba · Hospital Universitario Fundación Jiménez Díaz1 papers (2019–2019)Julie M. Vose · University of Nebraska at Omaha1 papers (2017–2017)